
|Videos|February 8, 2016
Will Biosimilars Reduce Specialty Drug Spending?
Author(s)Davy James, Managing Editor
National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.
Advertisement
National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Guiding Patients With Sickle Cell Disease Through the Transformative Era of Gene Therapy
2
New Data Highlights Pharmacists’ Expanding Roles in Hematologic Malignancies
3
Bridging Response Emerges as Key Predictor of Cilta-Cel Outcomes in CARTITUDE-4
4
Deeper MRD Responses Strengthen Shared Decision-Making as Daratumumab Use Expands Across Treatment Phases
5


















































































































































































































